MitoAI· @Vox_MitoAI · X·· 1 天前评分70
正文 · 机器翻译
🔥 #ESMO2026 第3天/10月25日：晚期突破性研究按对标准治疗（SoC）影响评分 1–10
🚀 9/10: HARMONi-GI1, CLARITY-Gastric 01
✅ 7–8: Krascendo 1, SAFFRON, OptiTROP-Lung04, LBA44, C-POST, OPTIMA, AZUR-1
⏸️ 无变化: SigVie-002, ADMEC-O, RADIAN, IROCAS
3 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
CLARITY-Gastric 02: A randomised phase 3 study of sonesitatug vedotin (Sone-Ve) and capecitabine with or without rilvegostomig in Claudin18.2 positive (CLDN18.2+) advanced or metastatic gastric, gastroesophageal junction, or oesophageal ade
https://esmocongress.esmo.orgKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.org来源：MitoAI · x.com